vofopitant

Small moleculeexperimental

Vofopitant (GR205171) is a drug which acts as an NK1 receptor antagonist. It has antiemetic effects as with other NK1 antagonists, and also shows anxiolytic actions in animals. It was studied for applications such as the treatment of social phobia and post-traumatic stress disorder, but did not prove sufficiently effective to be marketed. — Wikipedia

Clinical trial activity

3 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Sep 1, 2006 (NCT00383786)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COc1ccc(-n2nnnc2C(F)(F)F)cc1CN[C@H]1CCCN[C@H]1c1ccccc1
Mol. weight
432.45 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • gr205171
  • gr205171
  • gr205171
  • gr 205171
  • gr-205171
  • gr-205171
  • gr-205171
  • gr 226206
  • l-796,325
  • n-((2-methoxy-5-(5-(trifluoromethyl)-1h-tetrazol-1-yl)phenyl)methyl)-2-phenyl-3-piperidinamine
  • vofopitant
  • vofopitant
  • vofopitant
  • vofopitant
  • vofopitant

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00907985Phase 1May 1, 2009GlaxoSmithKline
NCT00606697Phase 2Dec 1, 2007GlaxoSmithKline
NCT00383786Phase 2Sep 1, 2006Baylor University, Icahn School of Medicine at Mount Sinai, National Institute of Mental Health (NIMH)
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit2222007
Baylor UniversityAcademic/Hospital1112006
Icahn School of Medicine at Mount SinaiAcademic/Hospital1012006
National Institute of Mental Health (NIMH)Government1012006
4 organizations
Page 1 / 1